OncoMatch/Clinical Trials/NCT06824467
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Is NCT06824467 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for ovarian cancer.
Treatment: Sacituzumab tirumotecan · Bevacizumab · H1 receptor antagonist · H2 receptor antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid mouthwash (dexamethasone or equivalent) — The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Has received 4 or more cycles of platinum-based doublet chemotherapy in first-line
Must have received: carboplatin-based chemotherapy — second-line
a total of 6 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer (OC)
Cannot have received: systemic anticancer therapy
Has received prior systemic anticancer therapy within 3 weeks or 5 half-lives (whichever is shorter) before allocation (Part 1) or randomization (Part 2)
Cannot have received: radiotherapy
Has received prior radiotherapy within 2 weeks of allocation (Part 1) or randomization (Part 2), or has radiation related toxicities, requiring corticosteroids
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham ( Site 0006) · Birmingham, Alabama
- Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) · New Haven, Connecticut
- Mount Sinai Cancer Center ( Site 0078) · Miami Beach, Florida
- Sarasota Memorial Hospital ( Site 0075) · Sarasota, Florida
- Florida Cancer Specialists East ( Site 7000) · West Palm Beach, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify